



American Academy of
Orthopaedic Surgeons®

AAOS

American Association of
Orthopaedic Surgeons

6300 North River Road Rosemont, IL 60018-4262
Phone 847/823-7186, 800/346-2267 Fax 847/823-8125 Fax-on-Demand 800/999-2939 Internet www.aaos.org 3721 60 JUL 13 P1:13

BOARD OF DIRECTORS

PRESIDENT

S. Terry Canale, M.D.
Campbell Clinic
1400 S. Germantown Road
Germantown, Tennessee 38138

FIRST VICE PRESIDENT

Richard H. Gelberman, M.D.
Washington University School of Medicine
Department of Orthopaedic Surgery
1 Barnes-Jewish Hospital Plaza Drive
West Pavillion, Suite 11300
St. Louis, Missouri 63110

SECOND VICE PRESIDENT

Vernon T. Tolo, M.D.
4650 Sunset Boulevard, MS69
Los Angeles, California 90027

SECRETARY

William J. Robb, III, M.D.
3633 W. Lake Avenue, Suite 300
Glenview, Illinois 60025-5803

TREASURER

Andrew J. Weiland, M.D.
Hospital for Special Surgery
535 E. 70th Street
New York, New York 10021

PAST PRESIDENTS

Robert D. D'Ambrosia, M.D.
New Orleans, Louisiana

James D. Heckman, M.D.
Needham, Massachusetts

MEMBERS-AT-LARGE

Joseph P. Iannotti, M.D., PhD
Cleveland, Ohio

Ramon L. Jimenez, M.D.
San Jose, California

Darren L. Johnson, M.D.
Lexington, Kentucky

Thomas P. Sculco, M.D.
New York, New York

CHAIR BOARD OF COUNCILORS

John R. Tongue, M.D.
Tualatin, Oregon

CHAIR-ELECT BOARD OF COUNCILORS

David A. Halsey, M.D.
Springfield, Vermont

SECRETARY BOARD OF COUNCILORS

Lowry Jones, Jr., M.D.
Kansas City, Missouri

CHAIR COUNCIL OF MUSCULOSKELETAL SPECIALTY SOCIETIES

Richard B. Welch, M.D.
San Francisco, California

CHAIR-ELECT COUNCIL OF MUSCULOSKELETAL SPECIALTY SOCIETIES

Gary E. Friedlaender, M.D.
New Haven, Connecticut

EXECUTIVE VICE PRESIDENT

William W. Tipton, Jr., M.D.
Rosemont, Illinois

Sixty-Eighth Annual Meeting
February 28—March 4, 2001
San Francisco, California

July 11, 2000

Jane E. Henney, MD
Commissioner
Food and Drug Administration (FDA)
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

Dear Dr. Henney:

The American Academy of Orthopaedic Surgeons (AAOS), representing over 16,000 Board certified orthopaedic surgeons, is pleased to take this opportunity to provide additional comments on the Proposed Rule: Suitability Determination for Donors of Human Cellular and Tissue-Based Products. (Published in the Federal Register on Thursday, September 30, 1999). (Docket No. 97N-484S). This letter supplements our correspondence dated December 21, 1999, which is attached.

In our initial letter, the AAOS questioned the FDA's definition of minimally manipulated tissue, the testing of bone graft substitutes for osteoinduction, and the exemption of family-related allogeneic tissue.

To reiterate, the AAOS fellowship is supportive of the proposed rule's overall requirements. As described in the proposed rule, essentially all of the tissue banks currently involved in the processing and distribution of musculoskeletal related tissues of concern to the AAOS are already in compliance with the proposed requirements.

Upon further consideration of the proposed rule, AAOS recommends that the FDA set allowable limits for chemical additives such as glycerol, to allograft tissues. While additives do not present a problem for disease transmission, in increased concentrations, chemical additives may present a problem for potential toxicities with donor tissues. AAOS encourages the FDA to consider limits for additive substances.

AAOS shares the concern of the FDA to assure that safe and effective products enter the marketplace. We remain committed to ensuring the availability of safe tissues and tissue-based products to enhance the

97N-484S



Jane E. Henney


July 11, 2000

Page 2

treatment of disease and injury. AAOS remains committed to protecting consumers and our patients.

Thank you for your efforts. We welcome the opportunity to work with you on this matter.

Sincerely,


William W. Tipton, Jr., MD
Executive Vice President



American Academy of
Orthopaedic Surgeons®

AAOS

American Association of
Orthopaedic Surgeons

6300 North River Road Rosemont, IL 60018-4262
Phone 847/823-7186, 800/346-2267 Fax 847/823-8125 Fax-on-Demand 800/999-2939 Internet www.aaos.org

December 21, 1999

Jane E. Henney, MD
Commissioner
Food and Drug Administration (FDA)
5630 Fishers Lane, Room 1061
Rockville, Maryland 20852

Dear Dr. Henney:

The American Academy of Orthopaedic Surgeons (AAOS), representing over 16,000 Board certified orthopaedic surgeons, is pleased to take this opportunity to comment on the Proposed Rule: Suitability Determination for Donors of Human Cellular and Tissue-Based Products. (Published in the Federal Register on Thursday, September 30, 1999). (Docket No. 97N-484S).

Inasmuch as the proposed rule enhances protections for the public regarding tissue transplantation, the AAOS fellowship is supportive of its overall requirements. As described in the proposed rule, essentially all of the tissue banks currently involved in processing and distribution of musculoskeletal related tissues of concern to the AAOS are already in compliance with the proposed requirements.

However, the AAOS would like to raise a few issues of concern with regard to FDA's regulation of human and cellular based tissue products.

First, we are unsure how the definition of "minimally manipulated tissue" may affect the FDA decisions in the regulation of particular tissue products. As it is currently written, this definition is confined to an extremely brief paragraph within the proposed rule. While the Center for Biologics, Evaluation and Research (CBER) 1997 guidance document "Proposed Approach to Regulation of Cellular and Tissue-Based Products" may provide some clarification as to what the FDA may define as "minimally manipulated tissue," the evolution of new methods, processing approaches, materials, and combinations of tissues, materials and cells, may create significant confusion or ambiguities as to what products do or do not fall within the FDA regulatory scope.

Future advancements in technologies and in the processing of human cellular and tissue-based products may put most tissue outside of the narrow definition of the proposed rule when in fact, a broader definition of "minimally

manipulated tissue," may be more appropriate. The Academy suggests that substantially more detailed guidance regarding this definition needs to be developed prior to the implementation of the rule.


Of additional concern, is that there is no requirement for osteoinductive bone graft substitutes derived from human tissues by minimally manipulative procedures to be tested for osteoinductive capacity by bioassay. The American Society for Testing and Materials (ASTM) has recently developed a draft standard for the testing of osteoinduction. Inclusion of an accepted standard may enhance public protection by providing improved quality control.

Finally, it is not clear why family-related allogeneic tissue donation is exempted from donor suitability requirements, particularly in light of potential social factors which may impair thorough disclosure of possible health-related risk factors in donor screening.

We share the concerns of the FDA in ensuring that safe and effective products enter the marketplace. We remain committed to ensuring the availability of safe tissues and tissue-based products to enhance the treatment of disease and injury and remain committed to protecting consumers and our patients.

Thank you for your efforts. We welcome the opportunity to work with you on these matters.

Sincerely,


William W. Tipton, Jr., MD
Executive Vice President

Align top of FedE

BOBBY DE LA CRUZ
APR. ACADEMY ORTHO SURGEONS
6300 N. RIVER ROAD
ROSEMONT

IL 60018-4262

SHIP DATE: 12JUL00
ACC # 060634130

ACTUAL WGT: 1 LBS SCALE

(708)823-7186

TO: DOCKETS MANAGEMENT BRANCH DOCK(301)443-8517
DIV. OF MGMT. SYSTEMS&POLICY/FDA
5630 FISHERS LANE(HFA-305 RM.1061)

ROCKVILLE

MD 20852

4172 6534 7131

FedEx

your use of this service is subject to the terms and conditions of the FedEx service agreement. For more information, please visit our website at www.fedex.com. © 2000 FedEx Corporation. All rights reserved.

REF: JILL NAATZ

STANDARD OVERNIGHT

THU

cad # 0044269 12JUL00

TRK# 4172 6534 7131

FORM
0201

Deliver by:

13JUL00

IAD AA

20852 -MD-US

XAGAIA



153078-077 RIT 0400 ::

The World On Tin
Five